BioStock: Xintela is preparing for progress in 2021

Xintela’s focused and goal-oriented work during 2020 led to the company reaching several milestones. Preparations are now underway for a clinical phase I/II study with XSTEM-OA, Xintela’s stem cell treatment for osteoarthritis. The study will be initiated when a manufacturing license is received from the Medical Products Agency enabling the company to produce stem cells in its own GMP facility. BioStock contacted CEO Evy Lundgren-Åkerlund regarding Xintela’s achievements during the past year and the plans for 2021.

Read the full article at biostock.se:
 
https://www.biostock.se/en/xintela-is-preparing-for-progress-in-2021/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se